These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23893036)

  • 41. Generalized estimating equation model to compare drug effects on synovitis of the dominant wrist in severe rheumatoid arthritis between tocilizumab versus adalimumab versus abatacept using high-resolution ultrasound.
    Chen YC; Chiu WC; Su FM; Chen JF
    Int J Rheum Dis; 2018 Sep; 21(9):1695-1700. PubMed ID: 29024421
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients.
    Tan BE; Lim AL; Kan SL; Lim CH; Tsang EEL; Ch'ng SS; Mohd Noor N; Mohd Jamid N; Teh CL; Joshua Thundyil R; Loh YL; Chong HC; Ong SG; Mohamed Ismail A; Lee YYL; Gun SC
    Rheumatol Int; 2017 Oct; 37(10):1719-1725. PubMed ID: 28695274
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice.
    Kaufmann J; Feist E; Roske AE; Schmidt WA
    Clin Rheumatol; 2013 Sep; 32(9):1347-55. PubMed ID: 23703358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
    Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K
    Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab.
    Hirabayashi Y; Ishii T;
    Clin Rheumatol; 2013 Jan; 32(1):123-7. PubMed ID: 23090655
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study.
    Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Fukaya N; Hayashi M; Tsuboi S; Kanayama Y; Funahashi K; Hanabayashi M; Hirabara S; Asai S; Yoshioka Y; Ishiguro N
    Rheumatology (Oxford); 2015 May; 54(5):854-9. PubMed ID: 25339638
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
    Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
    Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
    [TBL] [Abstract][Full Text] [Related]  

  • 50. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study.
    Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
    Semin Arthritis Rheum; 2018 Dec; 48(3):399-405. PubMed ID: 29673963
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety.
    Yoshida K; Tokuda Y; Oshikawa H; Utsunomiya M; Kobayashi T; Kimura M; Deshpande GA; Matsui K; Kishimoto M
    Rheumatology (Oxford); 2011 Nov; 50(11):2093-9. PubMed ID: 21890622
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis.
    Lee JS; Ahmad H; Shim SC; Bae SC; Song YW; Lee EY
    Patient; 2019 Jun; 12(3):319-326. PubMed ID: 30484084
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suppression of joint destruction with subcutaneous tocilizumab for Japanese patients with rheumatoid arthritis in clinical practice.
    Nakashima Y; Kondo M; Shono E; Ishinishi T; Tsukamoto H; Kuroda K; Maeyama A; Harada H; Maekawa M; Shimauchi T; Nagamine R; Jojima H; Yoshizawa S; Tsuru T; Otsuka T; Miyahara H; Suematsu E; Wada K; Yoshizawa S; Inoue Y; Fukuda T; Ikemura S; Haraguchi A
    Mod Rheumatol; 2020 Sep; 30(5):807-815. PubMed ID: 31580188
    [No Abstract]   [Full Text] [Related]  

  • 56. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
    Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
    Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
    Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
    Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study.
    Bird P; Nicholls D; Barrett R; de Jager J; Griffiths H; Roberts L; Tymms K; McCloud P; Littlejohn G;
    Int J Rheum Dis; 2017 Apr; 20(4):460-468. PubMed ID: 28205333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice.
    Narváez J; Magallares B; Díaz Torné C; Hernández MV; Reina D; Corominas H; Sanmartí R; LLobet JM; Rodriguez de la Serna A; Nolla JM
    Semin Arthritis Rheum; 2016 Feb; 45(4):386-90. PubMed ID: 26254548
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Rutherford AI; Subesinghe S; Hyrich KL; Galloway JB
    Ann Rheum Dis; 2018 Jun; 77(6):905-910. PubMed ID: 29592917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.